Introduction {#sec1}
============

Type 2 diabetes mellitus (T2DM) and post-transplant diabetes mellitus (PTDM), the latter also known as new-onset diabetes after transplantation (NODAT), are two major forms of multifactorial metabolic disorder. T2DM is a chronic disease, characterized by insulin resistance and impaired insulin secretion from pancreatic β-cells[@bib1]; PTDM is similar to T2DM in this respect. PTDM is not a separate disease on its own, but a symptom of an underlying metabolic disorder.[@bib2] Renal transplant (RT) recipients with PTDM/NODAT exhibit similar complications to those of T2DM patients in the general population, but at an accelerated rate of onset.[@bib3] Up until now, no clear risk factors for PTDM have been established. However, the following characteristics that appear to predispose patients to the development of PTDM have been identified: age, race, ethnicity, obesity, cadaver-donor kidney transplant, hepatitis C infection, metabolic syndrome, glucose intolerance, and immunosuppressive agents/drugs.[@bib4], [@bib5] Earlier reports have concluded that a family history of T2DM increases the risk of PTDM up to seven-fold. The use of immunosuppressive medications, such as calcineurin inhibitors (cyclosporin and tacrolimus) and corticosteroids, plays an important role in the pathogenesis of PTDM.[@bib6], [@bib7]

Several papers have reported that insulin resistance is an important factor in the pathophysiology of PTDM; a defect in insulin secretion may also play a role in the development of the disease.[@bib2], [@bib3], [@bib8] Genome wide association studies (GWASs) identified several single nucleotide polymorphisms (SNPs) that are associated with susceptibility to T2DM.[@bib9], [@bib10], [@bib11] A GWAS has identified a mutation in the potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) gene as an important disease-susceptibility factor associated with the pathogenesis of diabetes in Asian ethnic groups.[@bib12] KCNQ1 is present in adipose tissue and mediates insulin secretion; the mutation of the *KCNQ1* gene has been shown to be associated with susceptibility to T2DM[@bib13] and to PTDM.[@bib11], [@bib14] Candidate-gene studies have provided strong evidence that a common variant of the potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) gene is also associated with T2DM[@bib15] and PTDM.[@bib16] The variants of both the *KCNQ1* and *KCNJ11* genes are associated with reduced depolarization-evoked insulin exocytosis. In order to ascertain whether impaired β-cell function plays an important role in T2DM and PTDM, we examined the potential effect of these previously associated *KCNQ1* and *KCNJ11* variants on the risk of T2DM and PTDM following RT, in Asian Indian patients.

Materials and methods {#sec2}
=====================

Ethical approval {#sec2.1}
----------------

Ethical approval for this study was obtained from the ethical committee of Kamineni Hospital, Hyderabad, India, and written informed consent was obtained from all the patients who participated in the study.

Study design {#sec2.2}
------------

This was a case--control study carried out in the Department of Genetics and Molecular Medicine, Kamineni Hospital, Hyderabad, India. The study enrolled 640 Asian Indian subjects, 250 patients with T2DM, 250 healthy controls, and 140 patients who had undergone RT and been administered calcineurin inhibitors for \>3 months. All the RT patients underwent routine follow up at the Department of Nephrology, Kamineni Hospital; 42 of these patients developed PTDM/NODAT later, as diagnosed by the American Diabetes Association (ADA) criteria[@bib17], [@bib18] and were included in the study, whereas the remaining 98 were termed as non-PTDM patients and were no longer included. All the healthy controls were selected from the general population visiting the hospital, based on their having normal blood glucose levels and being non-obese. The inclusion or exclusion of T2DM cases, healthy controls, and RT patients has been described in our previous publication.[@bib18], [@bib19]

Blood test {#sec2.3}
----------

A total of 5 mL of peripheral blood was collected from the T2DM patients and healthy controls: 3 mL of the serum sample was used for biochemical analyses to confirm the disease diagnosis of T2DM patients, and 2 mL of the EDTA-blood sample was used for the molecular analysis of all the subjects who participated in the study. The clinical and biochemical assessments of T2DM cases and control subjects have been described in our previous studies.[@bib19]

PCR and RFLP analyses {#sec2.4}
---------------------

Genomic DNA was extracted from peripheral leucocytes using the salting-out technique, routinely used in our laboratory, as previously described.[@bib20] The DNA samples were stored at −80 °C until processed. Genotyping for *KCNQ1* (rs2283228) and *KCNJ11* (rs5210) variants was carried out via PCR-RFLP in a 25 μL reaction (Bangalore Genei kit; Bangalore Genei Pvt. Ltd., Bangalore, Karnataka, India), using an Applied Biosystems thermal cycler machine (Life Technologies, Carlsbad, CA, USA), and analyzed by agarose gel electrophoresis. The primers for both the SNPs have been published.[@bib21], [@bib22] Primers for PCR analyses were synthesized by Bio Serve Biotechnologies (BioServe Biotechnologies, Ltd., Hyderabad, India). The PCR procedure for both SNPs involved DNA denaturation at 95 °C for 5 min, amplification by 35 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C for 45 s, and a final extension at 72 °C for 5 min. The restriction enzymes, *Bs*rI (A^↓^CTGGT) and *Hpy1888*III (TCCT^↓^GA) (New England BioLabs Inc., Ipswich, MA, USA), were first tested with bacteriophage λ DNA to confirm their specificity. *Bsr*I was used to digest *KCNQ1* PCR products and *Hpy1888*III was used to digest *KCNJ11* PCR products for 4 h at 37 °C in a 20 μL reaction containing 2.5 μL of distilled water, 10 units of restriction enzyme per 15 μL of PCR product, and 2 μL of the appropriate restriction enzyme buffer. The digested PCR products were analyzed by electrophoresis in 3.5% agarose gels containing ethidium bromide ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}).Figure 1Digested PCR products of KCNQ1 on 3% agarose gel.Figure 2Depiction of digestion of KCNJ11 products on 3% agarose.

Statistical analysis {#sec2.5}
--------------------

Data are expressed as the mean ± SD. Statistical analyses were carried out using the SPSS software, version 21.0, for Windows (IBM Corp., New York, NY, USA). Allele and genotype frequencies were compared between patients and controls using the χ^2^ test or a two-sided Fisher\'s exact test (*p* \< 0.05 was considered significant). The χ^2^ test was used to compare genotype frequencies in T2DM patients vs. controls, and PTDM patients vs. controls, assuming both additive and recessive models. The Hardy--Weinberg equilibrium (HWE) was measured using the χ^2^ test for goodness of fit. A value of *p* \< 0.05 was considered to indicate a significant disequilibrium.

Results {#sec3}
=======

Characteristics of the T2DM patients {#sec3.1}
------------------------------------

This study comprised two groups, 250 T2DM patients and 250 healthy controls, from the South Indian population residing in Telangana or Andhra Pradesh; the comparison between the anthropometric and clinical characteristics of the study groups is shown in [Table 1](#tbl1){ref-type="table"}. The average age of the T2DM patients was (57.19 ± 8.22) years with a mean body mass index (BMI) of (27.5 ± 4.1) kg/m^2^, whereas the average age of the controls was (53.93 ± 6.32) years with a mean BMI of (25.8 ± 3.9) kg/m^2^. There was a significant difference in the levels of fasting blood sugar, post-lunch blood sugar, triglycerides, HDL cholesterol, and total cholesterol between the T2DM patients and controls (*p* \< 0.05). Gender, BMI, LDL cholesterol, and family history were not significantly associated with T2DM (*p* \> 0.05), although family history was closely associated with T2DM (58.4%).Table 1Quantifiable characteristics of type 2 diabetes mellitus patients and healthy controls.S. noCharacteristics*T2DM Cases* (*n* = 250)*Healthy Controls* (*n* = 250)*p* Value1Age (Years)41--82 (57.19 ± 8.22)41--60 (53.93 ± 6.32)0.00032Males/Females (%)138 (55.2%)/112 (44.8%)144 (57.6%)/106(42.4%)0.34613BMI (kg/m^2^)27.5 ± 4.125.8 ± 3.90.43064T2DM Interval13.1 ± 6.3NANA5FBS (mg/dL)143.61 ± 55.6693.54 ± 12.13\<0.00016PPBG (mg/dL)201.29 ± 25.25117.29 ± 19.070.00017Triglycerides (mg/dL)156.42 ± 78.97138.77 ± 53.69\<0.00018Total Cholesterol (mg/dL)183.95 ± 51.54175.06 ± 33.05\<0.00019HDL-C (mg/dL)88.72 ± 23.182.61 ± 20.6=0.0110LDL-C (mg/dL)38.76 ± 4.435.53 ± 4.1=0.265811Family History, *n* (%)146 (58.4%)138 (55.2%)=0.3745[^1]

Characteristics of PTDM study subjects {#sec3.2}
--------------------------------------

The clinical characteristics of PTDM patients are given in [Table 2](#tbl2){ref-type="table"}. In this study, 140 RT patients were selected and categorized as having PTDM or being non-PTDM, based on biochemical tests; 30% of RT recipients developed PTDM. We included the 42 patients diagnosed with PTDM in this study and excluded the 98 non-PTDM as subjects. There were 30 male subjects and 12 female subjects in the PTDM patient group; the mean age of the male and female subjects was similar, i.e., (39.39 ± 2.12) years and (40.0 1 ± 11.63) years, respectively. Of the 42 patients with PTDM, 22 (54%) received cyclosporin treatment, whereas 20 (47.6%) received tacrolimus. When we performed the t-test between PTDM and non-PTDM subjects, gender, weight, subjects with cyclosporine drugs (i.e., CsA, Tac) and along with the dosage were found statistically significant (*p* \< 0.05).Table 2Clinical characteristics of patients with post-transplant diabetes mellitus and non-post-transplant diabetes mellitus subjects.S. noBaseline characteristicsPTDM (*n* = 42)Non-PTDM (*n* = 98)*p* Value1Males/Females30/1275/230.0012Age: a) Males (Mean ± SD)39.39 ± 12.1239.55 ± 10.580.27b) Females (Mean ± SD)40.01 ± 11.6339.26 ± 10.870.583Weight: a) Males (Mean ± SD)62.73 ± 15.8166.03 ± 12.730.08b) Females (Mean ± SD)61.71 ± 16.9365.49 ± 13.680.094a) On CsA therapy22580.01b) On Tac therapy20400.025a) CsA Dose (mg)163.88 ± 57.4201.29 ± 76.860.03b) Tac Dose (mg)3.15 ± 1.243.11 ± 1.620.056a) C2 levels (ng/mL) CsA750 ± 299.031024.8 ± 353.420.23b) Trough levels (ng/mL) Tac9.55 ± 3.388.0 ± 3.320.867a) C2 levels/dose of CsA5.24 ± 2.595.52 ± 1.970.02b) Trough levels/dose of Tac3.62 ± 1.962.98 ± 1.490.02[^2]

Hardy--Weinberg equilibrium {#sec3.3}
---------------------------

The distribution of the genotype frequencies of *KCNQ1* and *KCNJ11* variants in case and control subjects is in accordance with the HWE. We have carried out the statistics for power analysis, and found to be 72%. The genotypic distribution of *KCNQ1* and *KCNJ11* variants and their allelic frequencies in all the patients (T2DM and PTDM) and controls in this study are given in [Table 3](#tbl3){ref-type="table"}.Table 3Genotype and allele distribution of *KCNQ1* and *KCNJ11* gene polymorphisms in patients with type 2 and post-transplant diabetes mellitus and in healthy controls.*KCNQ1* (rs2283228)T2DM\
N (%)Controls\
N (%)Odds ratio[a](#tbl3fna){ref-type="table-fn"} (95% CI)*p* ValuePTDM\
N (%)Non-PTDM\
N (%)Odds ratio[a](#tbl3fna){ref-type="table-fn"}^,^[b](#tbl3fnb){ref-type="table-fn"} (95% CI)*p* ValueN2502504298AA205 (82%)231 (92.4%)Reference--20 (47.6%)72 (73.5%)Reference--AC41 (16.4%)17 (6.8%)2.7(1.4, 4.9)0.000722 (52.4%)26 (26.5%)3.0(1.4, 6.4)0.003CC04 (1.6%)02 (0.8%)2.2 (0.4, 12.4)0.3300 (00)\*00 (00)\*3.5 (0.06, 183.7)0.50AC + CC45 (18%)19 (7.6%)2.6 (1.5, 4.7)0.000422 (52.4%)\*26 (26.5%)3.0(1.4, 6.3)0.003A451 (90.2%)479 (95.8%)Reference--62 (73.8%)170 (86.7%)Reference--C49 (9.8%)21 (4.2%)2.4 (1.4, 4.1)0.000522 (26.2%)26 (13.3%)2.3 (1.2, 4.3)0.008*KCNJ11* (rs5210)T2DM\
N (%)Controls\
N (%)Odds ratio[a](#tbl3fna){ref-type="table-fn"}\
(95% CI)*p* ValuePTDM\
N (%)Non-PTDM\
N (%)Odds Ratio[b](#tbl3fnb){ref-type="table-fn"} (95% CI)*p* ValueN2502504298AA101 (40.4%)136 (54.4%)Reference--18 (42.8%)84 (85.7%)Reference--AG109 (43.6%)81 (32.4%)1.8(1.2, 2.6)0.00212 (28.6%)08 (8.2%)7.0 (2.5, 19.5)0.0001GG40 (16%)33 (13.2%)1.6 (0.9, 2.7)0.0612 (28.6%)06 (6.1%)9.3 (3.0, 28.1)0.0001AG + GG149 (59.6%)114 (45.6%)1.7 (1.2, 2.5)0.00124 (57.2%)14 (14.3%)8.0 (3.4, 18.4)0.0001A311 (62.2%)353 (70.6%)Reference--48 (57.2%)176 (89.8%)Reference--G189 (37.8%)147 (29.4%)1.4 (1.1, 1.9)0.00436 (428%)20 (10.2%)6.6 (3.5, 12.4)\<0.0001[^3][^4]

Association of the rs2283228 variant with T2DM and PTDM in the case--control study {#sec3.4}
----------------------------------------------------------------------------------

In an analysis of the frequency distribution of alleles and genotypes, the C allele of the rs2283228 polymorphism showed a strong association with T2DM (AC vs. AA: OR = 2.7 \[95% CI: 1.4--4.9\], *p* = 0.0007, and C vs. A: OR = 2.4 \[95% CI: 1.4--4.1\], *p* = 0.0005). A significant difference was observed in the dominant genotype for T2DM patients vs. controls (AC + CC vs. AA: OR = 2.6 \[95% CI: 1.5--4.7\], *p* = 0.0004). We evaluated the rs2283228 polymorphism in PTDM patients vs. non-PTDM subjects (*n* = 98) that were not used for the T2DM patients. Significant differences were observed between the PTDM patients and non-PTDM subjects ([Table 3](#tbl3){ref-type="table"}). There was a strong association between PTDM and the polymorphism, which was similar to that between T2DM and the polymorphism (AC vs. AA: OR = 3.0 \[95% CI: 1.4--6.4\], *p* = 0.003, and C vs. A: OR = 2.3 \[95% CI: 1.2--4.3\], *p* = 0.008). In addition, the difference in the dominant genotype for PTDM patients was significantly different from that in the controls (AC + CC vs. AA: OR = 3.0 \[95% CI: 1.4--6.3\], *p* = 0.003).

Association of the rs5210 variant with T2DM and PTDM in the case--control study {#sec3.5}
-------------------------------------------------------------------------------

The frequency distribution of genotypes and alleles of the rs5210 polymorphism, in T2DM patients vs. controls, was determined in order to examine their association with diabetes risk ([Table 3](#tbl3){ref-type="table"}). The frequencies of the AA, AG, and GG genotypes are 40.4%, 43.6%, 16% in T2DM patients and 54.4%, 32.4%, 13.2% in control subjects, respectively. These results indicate an association between the rs5210 variant and T2DM risk in the overall analysis (AG vs. AA: OR = 1.8 \[95% CI: 1.2--2.6\], *p* = 0.002). We observed a significant difference between the allele frequencies in T2DM patients and controls (G vs. A: OR = 1.4 \[95% CI: 1.1--1.9\], *p* = 0.004).

We also assessed the rs5210 variant in PTDM patients, as shown in [Table 3](#tbl3){ref-type="table"}. The genotype frequencies for AA, AG, and GG in PTDM patients vs. non-PTDM subjects are 42.8%, 28.6%, and 28.6% vs. 85.7%, 8.2% and 6.1%. The GG genotype is more prevalent in PTDM compared to T2DM patients. There are statistically significant differences between both the genotypic distribution and the allelic frequency in PTDM patients and non-PTDM subjects (AG + GG vs. AA: OR = 8.0 \[95% CI: 3.4--18.4\], *p* = 0.0001, and G vs. A: OR = 6.6 \[95% CI: 3.5--12.4\], *p* \< 0.0001).

Discussion {#sec4}
==========

In this case--control study, we investigated the association of *KCNQ1* (rs2283228) and *KCNJ11* (rs5210) gene polymorphisms with T2DM and PTDM in Asian Indians. Previous studies of the association between different *KCNQ1* and *KCNJ11* SNPs and T2DM were carried out in different populations.[@bib21], [@bib22], [@bib23], [@bib24], [@bib25] However, there are no previous reports of studies that have been carried out with these SNPs (i.e., rs2283228 in *KCNQ1* gene and rs5210 in *KCNJ11* gene) in the Asian Indian population. To the best of our knowledge, only a few studies have addressed the influence of *KCNQ1* and *KCNJ11* polymorphisms on the risk or pathogenesis of T2DM in Asian Indians.[@bib26], [@bib27], [@bib28] Additionally, we intended to investigate the association of *KCNQ1* (rs2283228) and *KCNJ11* (rs5210) gene polymorphisms with both T2DM and PTDM. The present study is the first to evaluate the distribution of rs2283228 and rs5210 polymorphisms in Asian Indian patients with PTDM, and we simultaneously conducted an evaluation of patients with T2DM from the same population; both groups of patients were assessed with healthy controls for T2DM subjects and non-PTDM for PTDM subjects. The results of the present study reveal that there is an association between *KCNQ1* and *KCNJ11* gene polymorphisms and both T2DM and PTDM in Asian Indians.

T2DM and PTDM represent different etiologies for the same complex disease, and several lines of evidence support the hypothesis that susceptibility to PTDM, like in the case of T2DM, has a genetic component. Although no systematic studies have evaluated this hypothesis, family studies suggest that instances of PTDM aggregate within families with a history of T2DM.[@bib29] PTDM is well defined, as sustained hyperglycemia developing in any patient with/without a family history of diabetes before transplantation, and meets the present diagnostic criteria from the ADA or WHO.[@bib30] Both the diseases (T2DM and PTDM) show a correlation with changes in the *KCNQ1* and *KCNJ11* genes. These genes are located on chromosome 11p13--p12 and 11p15.1. The *KCNQ1* gene encodes the pore-forming subunit of a voltage-gated potassium channel that plays a key role in the repolarization of the cardiac-action potential as well as in the transport of water and salts in epithelial tissues.[@bib31] KCNQ1 is expressed in pancreatic β-cells, and KCNJ11 plays a strategic role in insulin secretion by glucose-stimulated pancreatic β-cells.

A meta-analysis study by Liu et al[@bib31] demonstrated a positive association between the *KCNQ1* rs2283228 polymorphism and T2DM. The rs2283228 variant, previously associated with T2DM in European (Danish), but not in Chinese (Singaporean) and Arab (Tunisian) populations,[@bib21], [@bib32], [@bib33] was associated with T2DM in Asian Indians. The susceptibility-conferring C allele of the rs2283228 variant was associated with increased fasting glucose levels and impaired β-cell function in Asians.[@bib34] Previous studies from the Caucasian and Korean populations, has identified the positive association of the *KCNQ1* gene with PTDM[@bib11], [@bib14]; the same positive association was observed with PTDM in Asian Indian transplant recipients in the present study.

Five studies have investigated the association between the rs5210 polymorphism in the *KCNJ11* gene and T2DM; these studies included meta-analyses that found this association to be significantly heterogeneous (*p* = 0.02).[@bib35] The rs5210 polymorphism has been shown to be associated with T2DM in Finnish, Korean, and Mexican populations,[@bib22], [@bib36], [@bib37] and our results in Asian Indian T2DM patients are consistent with the results of these studies. There have been two studies carried out in PTDM patients in relation to the *KCNJ11* gene, i.e., Tavira et al[@bib16] reported that PTDM was associated with the rs5219 polymorphism in the Caucasian Spanish population, and Kurzawski et al[@bib38] carried out an assessment of the rs5215 polymorphism in the Caucasian Polish population and reported that it was not associated with PTDM. Our study was carried out in the Asian Indian population, and we identified that the rs5210 polymorphism was associated with PDTM in a similar way as it was associated with T2DM.

Limitations of the current study include the small number of patients confirmed with PTDM (*n* = 42) and our selection of only one SNP from each gene. We had missed out the glucose values for PTDM and non-PTDM subjects, which could be another limitation of our study. We also did not consider the interactions between the gene and its protein, which could require further studies. We have conducted the present study with single SNPs of the *KCNQ1* and *KCNJ11* genes and found these to be associated with both T2DM and PTDM in Asian Indian patients.

Conclusion {#sec5}
==========

In conclusion, we conclude that there is a significant association between the *KCNQ1* and *KCNJ11* genes and the risk of developing T2DM and PTDM in Asian Indians. Further studies are needed to confirm these findings in different ethnicities, together with functional studies.
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[^1]: NA: Not analyzed/Not applicable.

[^2]: T-test was performed between PTDM and non-PTDM subjects to obtain the *p* Values.

[^3]: Crude odds ratio (95% CI).

[^4]: Odds ratio (95% CI) Adjusted for Yates correction.
